[
  {
    "question": "Child with facial port wine stain. CT brain showed trim-like calcification. Diagnosis:",
    "option_a": "Sturge weber syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Sturge\u2010Weber syndrome is a neurocutaneous disorder (a phakomatosis) characterized by a facial port\u2010wine stain (typically along the trigeminal nerve distribution), leptomeningeal angiomas, and ocular abnormalities such as glaucoma. The disorder results from a somatic mosaic mutation in the GNAQ gene. This mutation leads to abnormal vascular development in the skin and leptomeninges. The abnormal vessels cause chronic hypoxia and calcification in the adjacent cortex, producing the classic \u2018tram\u2010track\u2019 (or trim\u2010like) calcifications seen on CT imaging. Children often present with the characteristic facial port\u2010wine stain visible at birth. As they age, seizures, hemiparesis, and cognitive impairment may develop due to the underlying leptomeningeal angiomatosis. The imaging finding of \u2018tram\u2010track\u2019 calcifications is a radiologic hallmark and correlates with the chronic nature of the leptomeningeal vascular malformations. Diagnosis is primarily clinical, supported by neuroimaging. CT scans reveal calcifications, while MRI can detail leptomeningeal involvement. Differential diagnoses include tuberous sclerosis (characterized by cortical tubers and subependymal nodules) and other neurocutaneous syndromes. However, the combination of facial port\u2010wine stain and tram\u2010track calcifications is almost pathognomonic for Sturge\u2010Weber syndrome. Management is symptomatic and multidisciplinary. First\u2010line therapy focuses on seizure control using antiepileptic drugs with an emphasis on those with favorable safety profiles in pregnancy and lactation (e.g., lamotrigine, levetiracetam). Ocular issues such as glaucoma should be managed in conjunction with an ophthalmologist. Laser therapy may be considered for the port\u2010wine stain. There is no definitive cure, so regular monitoring and supportive therapies are essential. Option A (Sturge\u2010Weber syndrome) is correct because the child\u2019s facial port\u2010wine stain and CT finding of tram\u2010track calcifications are classic features of the disease. The other options are not provided and would not fit this clinical picture. 1. A facial port\u2010wine stain in the distribution of the trigeminal nerve is a critical diagnostic clue. 2. \u2018Tram\u2010track\u2019 calcifications on CT scans are highly suggestive of chronic leptomeningeal involvement in Sturge\u2010Weber syndrome. Recent studies have reinforced the role of GNAQ mutations in the pathogenesis of Sturge\u2010Weber syndrome, and emerging treatments targeting vascular anomalies (including anti\u2010VEGF approaches) are under investigation to improve neurological outcomes.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "4 years old male patient with microcephaly, seizure, had brown hair musty odor urine,",
    "option_a": "Biotinidase deficiency.",
    "option_b": "Phenylketonuria",
    "option_c": "Marble syrup,",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Phenylketonuria (PKU) is an inborn error of metabolism caused by a deficiency of the enzyme phenylalanine hydroxylase. This leads to an accumulation of phenylalanine and its toxic metabolites. The enzyme deficiency prevents the conversion of phenylalanine to tyrosine, causing elevated levels of phenylalanine and build\u2010up of phenylketones that impart a characteristic musty odor to urine. The neurotoxic effects of high phenylalanine concentrations can lead to seizures and intellectual disability, particularly if the condition is left untreated. Clinically, untreated PKU presents with developmental delay, seizures, and often a musty odor in bodily secretions such as urine. Although classic descriptions mention lighter or 'blond' hair due to reduced melanin synthesis, there can be variability in presentation. The presence of microcephaly further reflects the adverse neurodevelopmental impact of untreated PKU. Newborn screening via the Guthrie test or tandem mass spectrometry is critical for early detection. Confirmatory testing involves measuring blood phenylalanine levels. Differential diagnoses include biotinidase deficiency (often presenting with alopecia, dermatitis, and metabolic acidosis) and maple syrup urine disease (which has a distinct sweet, maple syrup odor). The cornerstone of management is a lifelong low\u2010phenylalanine diet initiated as early as possible to prevent neurological damage, along with tyrosine supplementation. In pregnant women with PKU, strict dietary control is essential to prevent maternal PKU syndrome, which can lead to congenital malformations in the fetus. For lactating mothers with PKU, dietary management remains crucial to minimize phenylalanine exposure through breast milk. Option B (Phenylketonuria) is correct given the clinical features of seizures, microcephaly, and the musty odor of urine. Option A (Biotinidase deficiency) is incorrect because it typically involves alopecia and dermatitis, while Option C (Marble syrup) likely refers to maple syrup urine disease, which has a different clinical and biochemical profile. 1. Newborn screening for PKU is life\u2010saving, emphasizing the importance of early diagnosis. 2. The musty odor of urine is a hallmark of PKU and should prompt metabolic evaluation. Recent advances include the use of tetrahydrobiopterin (BH4) in BH4\u2010responsive cases and ongoing research into gene therapy. Current guidelines stress early dietary intervention to optimize neurodevelopmental outcomes.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "9 months of age with a history of developmental delay, atonic spasm for seconds, attached ECG (hypsarrhythmia), What is the diagnosis?",
    "option_a": "infantile spasm",
    "option_b": "sever myoclonus of infancy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Infantile spasms, also known as West syndrome, is an epileptic encephalopathy characterized by a triad of infantile spasms, an abnormal interictal EEG pattern (hypsarrhythmia), and developmental regression. The precise etiology of infantile spasms is variable and can be symptomatic of underlying brain lesions, metabolic disorders, or genetic abnormalities. The disorganized, chaotic electrical brain activity results in the characteristic EEG pattern of hypsarrhythmia. Typically presenting between 3 and 12 months of age, infantile spasms manifest as brief, often clustered muscle contractions that may be flexor, extensor, or atonic in nature. The presence of developmental delay alongside the EEG finding of hypsarrhythmia clinches the diagnosis. The clinical description here of an atonic spasm lasting seconds fits well within this syndrome. Diagnosis is established through clinical evaluation and confirmed by EEG showing hypsarrhythmia. Differential diagnoses include other early-onset seizure syndromes such as myoclonic seizures or benign infantile seizures, which do not exhibit the chaotic EEG pattern seen in West syndrome. First-line treatment typically involves adrenocorticotropic hormone (ACTH) or high-dose steroids. Vigabatrin is preferred in cases associated with tuberous sclerosis. Second-line treatment options include other antiepileptic drugs in refractory cases. Although the primary patient is an infant, when treating breastfeeding mothers on medication (if applicable), agents with lower lactation transfer and lower teratogenic risks are chosen. Option A (infantile spasm) is the correct diagnosis based on the age, seizure characteristics, and hypsarrhythmic EEG. Option B (severe myoclonus of infancy) does not match the typical EEG or clinical presentation of this syndrome. 1. Early recognition of infantile spasms is critical since prompt treatment can improve long-term outcomes. 2. The EEG pattern of hypsarrhythmia is virtually diagnostic of West syndrome. Recent guidelines favor early low-dose ACTH treatments to minimize side effects while ensuring efficacy. Vigabatrin continues to be the preferred agent in tuberous sclerosis-related cases, with ongoing studies optimizing dosing regimens.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of child with caf\u00e9 au lait spot, axillary freckling and Lisch nodules:",
    "option_a": "NF type 1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Neurofibromatosis type 1 (NF1) is a genetic neurocutaneous disorder characterized by multiple caf\u00e9-au-lait spots, axillary or inguinal freckling, and Lisch nodules (iris hamartomas), among other features. NF1 is caused by mutations in the NF1 gene, which encodes the protein neurofibromin, a tumor suppressor involved in regulating cell growth via the RAS/MAPK pathway. Loss of function of neurofibromin leads to uncontrolled cell proliferation and the formation of both benign and malignant tumors. Patients with NF1 typically develop multiple caf\u00e9-au-lait macules, freckling in skin folds (especially axillary regions), and Lisch nodules detectable on slit-lamp eye examination. Neurological involvement may include learning disabilities and, in some cases, the development of optic pathway gliomas. Diagnosis is primarily clinical, based on meeting the NIH diagnostic criteria for NF1. Differential diagnoses include NF type 2, which is characterized more by bilateral vestibular schwannomas and fewer cutaneous findings, and other phakomatoses like tuberous sclerosis, which has a different constellation of skin findings. Management is largely supportive and involves regular monitoring for associated complications (e.g., optic gliomas, skeletal deformities, hypertension). A multidisciplinary approach is crucial. In women with NF1 who are pregnant or lactating, additional monitoring is recommended because of the potential for increased tumor growth and obstetric complications, and genetic counseling is advised. Option A (NF type 1) is correct because the presence of caf\u00e9-au-lait spots, axillary freckling, and Lisch nodules fulfill the diagnostic criteria for NF1. Other options, though not listed here, would likely represent conditions with overlapping but non-diagnostic findings. 1. The combination of caf\u00e9-au-lait spots, axillary freckling, and Lisch nodules is highly indicative of NF1. 2. NF1 requires lifelong surveillance for potential complications, including tumors and cardiovascular issues. Recent research is focusing on genotype-phenotype correlations in NF1 to better predict outcomes and tailor management strategies. Multidisciplinary guidelines now emphasize regular screening and genetic counseling to optimize patient care.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of child with rash in the face, contralateral hemiparesis, and radiographic finding is one of gyral calcifications giving a tram-track appearance : answer",
    "option_a": "NF1",
    "option_b": "NF2",
    "option_c": "sturge weber",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Pediatric Neurology",
    "explanation": "Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by a facial capillary malformation (often a port-wine stain in the distribution of the trigeminal nerve), leptomeningeal angiomas, and ocular abnormalities. The classic imaging finding includes gyral calcifications with a 'tram-track' appearance, which is highly indicative of this condition. The syndrome is caused by a somatic mosaic mutation in the GNAQ gene, leading to dysplastic blood vessels in the leptomeninges and skin. The abnormal vascular proliferation results in chronic ischemia and subsequent calcification of the adjacent cerebral cortex. This progressive calcification is what produces the 'tram-track' appearance seen on CT scans. Children with SWS often present with a port-wine stain on the face (typically along the distribution of the trigeminal nerve), seizures (which can be focal or generalized), and neurological deficits such as contralateral hemiparesis. The presence of the tram-track calcifications on imaging correlates with the extent and duration of leptomeningeal involvement, hinting at the severity of the neurological impairment. Diagnosis is primarily clinical, supported by neuroimaging. Differential diagnoses include other neurocutaneous syndromes like tuberous sclerosis (which features cortical tubers and subependymal nodules) and neurofibromatosis, but these conditions lack the specific facial port-wine stain and pattern of leptomeningeal involvement seen in SWS. CT scans typically reveal the characteristic gyral calcifications, while MRI can define the extent of leptomeningeal angiomas. The mainstay of management involves control of seizures with first-line anti-epileptic medications such as levetiracetam or sodium valproate, and regular ophthalmologic evaluations to detect and manage glaucoma. For refractory seizures, surgical treatments\u2014including procedures like hemispherectomy\u2014may be considered. In the context of pregnancy, pregnant patients should be managed with medications that pose minimal teratogenic risk, and drug choices may need adjustment during lactation to ensure safety for the infant. A multidisciplinary approach involving neurology, ophthalmology, and dermatology is recommended. Option A (NF1) and Option B (NF2) are neurocutaneous syndromes but have different clinical features: NF1 involves caf\u00e9-au-lait spots, Lisch nodules, and neurofibromas, whereas NF2 is primarily associated with bilateral acoustic neuromas and other central nervous system tumors. Neither of these conditions presents with the facial port-wine stain or the tram-track calcifications. Option C, Sturge-Weber syndrome, fits the clinical description provided (facial rash, contralateral hemiparesis, and tram-track calcifications), confirming it as the correct answer. 1. The presence of a port-wine stain in the distribution of the trigeminal nerve is a clinical hallmark of SWS. 2. 'Tram-track' calcifications on imaging are pathognomonic for leptomeningeal involvement in SWS. 3. Early seizure onset and neurological deficits in SWS can indicate a more severe disease course. Recent research has underscored the significance of early seizure control and regular ophthalmologic surveillance in improving neurodevelopmental outcomes in SWS. Advances in our understanding of the GNAQ mutation are paving the way for potential targeted therapies. Current guidelines emphasize a cautious approach when prescribing antiepileptic drugs during pregnancy and lactation, focusing on minimizing teratogenic risks while adequately controlling seizures.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "To act in the best interest of the patient:",
    "option_a": "Justice",
    "option_b": "Beneficence",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Beneficence is one of the core ethical principles in medicine. It involves acting in the best interest of the patient by promoting good and preventing harm. Although not a pathophysiological concept, beneficence underpins all clinical decisions \u2013 ensuring that the treatments and interventions offered have a favorable risk\u2010benefit balance according to the best available evidence. In practice, beneficence is reflected when clinicians opt for treatments that maximize patient well\u2010being, adhere to evidence-based medicine, and take steps to avoid harm. This principle is integrated into daily decision-making and patient management. While there is no 'diagnosis' with an ethical principle, it is essential to differentiate beneficence from related terms such as non-maleficence (do no harm), justice (fairness and equity), and autonomy (patient\u2019s right to self-determination). Each of these principles guides different aspects of patient care. In clinical management, beneficence means choosing interventions that offer the maximum therapeutic advantage. Guidelines recommend first-line therapies that are both effective and safe. In special populations such as pregnant or lactating patients, clinicians must tailor their approach by selecting treatments where the benefit outweighs potential risks, always adhering to latest safety guidelines. Option A (Justice) refers to fairness and equal treatment, which is a different ethical concept. Option B (Beneficence) correctly describes the responsibility to act in the patient\u2019s best interest. Options C and D are not provided, making B the only complete and correct answer. 1. Beneficence requires balancing benefit with potential harm. 2. In practice, combining beneficence with non-maleficence is essential to ethical patient care. Recent guidelines in bioethics continue to affirm beneficence as a guiding principle in evidence-based practice, emphasizing patient-centered care and individualized risk-benefit assessment.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Definition of informed consent:",
    "option_a": "Explain to the patient the purse of the study",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Informed consent is a fundamental process by which a patient is provided with all relevant information to make an autonomous decision about their care or research participation. It is rooted in respect for patient autonomy. While this concept does not involve biological processes, its underpinning is in ensuring that the decision-making process is free from coercion and is based on a clear understanding of the information provided. Clinically, informed consent is critical whenever procedures, interventions, or research studies are considered. It ensures that patients understand the benefits, risks, alternatives, and potential outcomes before making decisions about their care. The 'diagnosis' of informed consent involves ensuring that all components \u2013 disclosure, understanding, voluntariness, competence, and consent \u2013 are met. Inadequate informed consent may be suspected if there is evidence of coercion, poor communication, or misunderstanding. Effective informed consent involves a tiered approach: first, complete disclosure of relevant information; second, checking for patient understanding; and third, ensuring voluntariness. Special considerations should be given for pregnant or lactating patients by providing tailored information regarding potential risks and benefits to both mother and child, following updated guidelines from professional bodies and regulatory authorities. Option A, which only mentions 'explaining the purpose of the study', is incomplete as it does not cover the full spectrum of informed consent (risks, benefits, alternatives, etc.). Without visible text for options B, C, and D, the marked answer D is presumed to incorporate the complete definition, which aligns with standard ethical definitions of informed consent. 1. Informed consent is a process, not a one-time event. 2. It must be documented, ensuring that the patient\u2019s questions are fully answered. Recent ethical guidelines and revisions to international declarations (such as the Declaration of Helsinki) emphasize that informed consent must be an iterative, clear, and comprehensive process, constantly updated to reflect emerging evidence and patient-centered care principles.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "A doctor saw one patient in his governmental hospital, then asked him to be seen in his private OPD",
    "option_a": "",
    "option_b": "(as marked) is interpreted to reflect that this practice is generally unethical due to conflict of interest. Other options that might suggest acceptability based solely on patient agreement or procedural technicalities would be flawed due to the inherent power imbalance and violation of ethical standards.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuropsychiatry",
    "explanation": "This question touches on the ethics of dual practice and conflict of interest where a physician might exploit their position for personal gain by transferring patients from a public to a private setting. Not applicable in a biological sense, but ethically, the mechanism involves a conflict between the physician\u2019s duty to the patient and personal financial interests. This dual role can compromise the trust inherent in the physician-patient relationship. In real-world settings, physicians must avoid any action that may be perceived as prioritizing personal financial benefit over patient welfare. Asking a patient seen in a government hospital to continue care in a private practice may be perceived as coercive or exploitative. Clinicians should differentiate between legitimate referrals based on best interest and those driven by personal gain. Differential considerations include: appropriate patient choice, explicit institutional guidelines, and whether proper consent was obtained before making the referral. Guideline recommendations typically advise that physicians avoid situations where personal financial interests could conflict with patient care. First-line management is strict adherence to institutional policies and professional ethical codes. In cases involving pregnant or lactating patients, additional caution is warranted to avoid any perception of exploitation and to ensure that care options are presented neutrally, respecting both patient autonomy and well-being. Although the exact wording of each option is not provided, Option B (as marked) is interpreted to reflect that this practice is generally unethical due to conflict of interest. Other options that might suggest acceptability based solely on patient agreement or procedural technicalities would be flawed due to the inherent power imbalance and violation of ethical standards. 1. Always maintain a clear separation between public service and private practice to avoid conflicts of interest. 2. Transparency with patients and adherence to institutional policies are essential to uphold ethical standards. Recent reviews in medical ethics as well as guidelines from bodies like the AMA and local medical councils underscore that any potential conflict of interest should be managed by maintaining strict boundaries between public and private practice, ensuring that patient welfare remains paramount.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient Dx to have serious disease, he had no family members, how to break the bad news",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Breaking bad news is a sensitive communication task that requires empathy, clear language, and structured delivery. Protocols like SPIKES (Setting, Perception, Invitation, Knowledge, Emotions, and Summary/Strategy) are designed to standardize this process ensuring patient-centered care. While not biological, the process of receiving serious news can trigger significant emotional responses (including shock, denial, and grief) that can adversely affect the patient\u2019s psychological state and potentially their physiological response to illness. Effective communication when conveying a serious diagnosis is crucial. Poorly delivered news can erode trust, worsen patient anxiety, and impair subsequent treatment adherence, while a well-delivered message can help patients process information and engage in their care planning. When evaluating methods to deliver bad news, it is important to differentiate approaches that confirm patient understanding (using plain language, assessing emotional response, and allowing time for questions) versus those that are abrupt, overly technical, or dismissive of emotional needs. The tiered approach includes: \u2022 First-line: Prepare the environment (private, quiet setting) and use the SPIKES protocol. \u2022 Second-line: Allow the patient to express emotions and validate their feelings. \u2022 Third-line: Summarize the discussion and outline the next steps, making sure to assess the patient\u2019s understanding. Special consideration in patients with no immediate family entails ensuring additional support (e.g., mental health services or referrals to supportive care teams), and this approach remains the same for all patients including those who are pregnant or lactating \u2013 ensure that potential implications for maternal or child health are discussed if relevant. The provided options (A, B, C, D) were either incomplete or did not encapsulate the comprehensive approach necessary for breaking bad news. The option marked as A does not adequately reflect the need to integrate empathy, clarity, patient involvement, and support as outlined in evidence-based communication protocols. Thus, the correct answer is that none of the provided options fully capture the ideal approach. 1. Always set a quiet and private environment before delivering serious news. 2. Use established protocols such as SPIKES to guide the conversation and ensure all patient needs are addressed. Recent studies and updated communication guidelines emphasize that breaking bad news should be viewed as a process rather than a single event. The SPIKES protocol\u2014supported by current research\u2014remains the gold standard for facilitating patient understanding and emotional processing during difficult discussions.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Non-beneficence",
    "option_a": "",
    "option_b": "and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuropsychiatry",
    "explanation": "The concept centers on the idea of non\u2010beneficence, which is essentially the failure to promote the patient\u2019s best interests. In ethical terms, beneficence is the active duty to help and improve a patient\u2019s welfare. Non\u2010beneficence, although not classically listed as one of the key ethical principles, is used to describe situations where this positive duty is not fulfilled. It is important not to confuse this with nonmaleficence, which focuses on avoiding harm. While pathophysiology usually refers to disease mechanisms, in ethics the underlying mechanism is the lack of action to promote benefit. In this context, non\u2010beneficence occurs when a clinician, due to oversight or other factors, fails to take positive steps that would contribute to a patient\u2019s well\u2010being. Contemporary discussions stress that clinicians must actively engage in beneficent behaviors rather than simply avoiding harm. In clinical practice, a lapse of beneficence can be seen when appropriate therapies, support, or interventions are not offered to the patient, potentially leading to worsening outcomes. This concept is central to medical ethics and quality care, ensuring that all patients receive interventions aimed at improving their health. Although not a disease diagnosis, understanding non\u2010beneficence involves differentiating it from: (1) Beneficence (the duty to actively help), (2) Nonmaleficence (the duty to avoid harm), (3) Autonomy (respecting patient choices even if they conflict with beneficence), and (4) Justice (fairness in care delivery). In clinical settings, the approach is to ensure that beneficence is maximized. This involves keeping current with evidence based guidelines, individualized patient care planning, and an ethical commitment to improving patient outcomes. In scenarios involving special populations (eg, pregnant or lactating patients), beneficence dictates that clinicians consider the best available evidence to promote both maternal and fetal/infant health. Since no explicit options were provided except for the marking of option B and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle. 1. Beneficence requires active promotion of patient welfare, while nonmaleficence demands the avoidance of harm. 2. Non\u2010beneficence is best understood as a failure to act rather than an active wrong. 3. Clarity in ethical definitions prevents mismanagement and medicolegal issues. Recent ethical literature emphasizes the importance of active beneficence in health care, noting that omissions in care can lead to legal and professional repercussions. Updated guidelines in clinical ethics continually stress a balanced approach that supports patient welfare, particularly in complex cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient refuse admission & refuse to sign LAMA",
    "option_a": "",
    "option_b": "and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuropsychiatry",
    "explanation": "The concept centers on the idea of non\u2010beneficence, which is essentially the failure to promote the patient\u2019s best interests. In ethical terms, beneficence is the active duty to help and improve a patient\u2019s welfare. Non\u2010beneficence, although not classically listed as one of the key ethical principles, is used to describe situations where this positive duty is not fulfilled. It is important not to confuse this with nonmaleficence, which focuses on avoiding harm. While pathophysiology usually refers to disease mechanisms, in ethics the underlying mechanism is the lack of action to promote benefit. In this context, non\u2010beneficence occurs when a clinician, due to oversight or other factors, fails to take positive steps that would contribute to a patient\u2019s well\u2010being. Contemporary discussions stress that clinicians must actively engage in beneficent behaviors rather than simply avoiding harm. In clinical practice, a lapse of beneficence can be seen when appropriate therapies, support, or interventions are not offered to the patient, potentially leading to worsening outcomes. This concept is central to medical ethics and quality care, ensuring that all patients receive interventions aimed at improving their health. Although not a disease diagnosis, understanding non\u2010beneficence involves differentiating it from: (1) Beneficence (the duty to actively help), (2) Nonmaleficence (the duty to avoid harm), (3) Autonomy (respecting patient choices even if they conflict with beneficence), and (4) Justice (fairness in care delivery). In clinical settings, the approach is to ensure that beneficence is maximized. This involves keeping current with evidence based guidelines, individualized patient care planning, and an ethical commitment to improving patient outcomes. In scenarios involving special populations (eg, pregnant or lactating patients), beneficence dictates that clinicians consider the best available evidence to promote both maternal and fetal/infant health. Since no explicit options were provided except for the marking of option B and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle. 1. Beneficence requires active promotion of patient welfare, while nonmaleficence demands the avoidance of harm. 2. Non\u2010beneficence is best understood as a failure to act rather than an active wrong. 3. Clarity in ethical definitions prevents mismanagement and medicolegal issues. Recent ethical literature emphasizes the importance of active beneficence in health care, noting that omissions in care can lead to legal and professional repercussions. Updated guidelines in clinical ethics continually stress a balanced approach that supports patient welfare, particularly in complex cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Female with abnormal movements and greenish corneal ring (KF rings) What\u2019s the most common psychiatric presentation:",
    "option_a": "Depression",
    "option_b": "and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuropsychiatry",
    "explanation": "The concept centers on the idea of non\u2010beneficence, which is essentially the failure to promote the patient\u2019s best interests. In ethical terms, beneficence is the active duty to help and improve a patient\u2019s welfare. Non\u2010beneficence, although not classically listed as one of the key ethical principles, is used to describe situations where this positive duty is not fulfilled. It is important not to confuse this with nonmaleficence, which focuses on avoiding harm. While pathophysiology usually refers to disease mechanisms, in ethics the underlying mechanism is the lack of action to promote benefit. In this context, non\u2010beneficence occurs when a clinician, due to oversight or other factors, fails to take positive steps that would contribute to a patient\u2019s well\u2010being. Contemporary discussions stress that clinicians must actively engage in beneficent behaviors rather than simply avoiding harm. In clinical practice, a lapse of beneficence can be seen when appropriate therapies, support, or interventions are not offered to the patient, potentially leading to worsening outcomes. This concept is central to medical ethics and quality care, ensuring that all patients receive interventions aimed at improving their health. Although not a disease diagnosis, understanding non\u2010beneficence involves differentiating it from: (1) Beneficence (the duty to actively help), (2) Nonmaleficence (the duty to avoid harm), (3) Autonomy (respecting patient choices even if they conflict with beneficence), and (4) Justice (fairness in care delivery). In clinical settings, the approach is to ensure that beneficence is maximized. This involves keeping current with evidence based guidelines, individualized patient care planning, and an ethical commitment to improving patient outcomes. In scenarios involving special populations (eg, pregnant or lactating patients), beneficence dictates that clinicians consider the best available evidence to promote both maternal and fetal/infant health. Since no explicit options were provided except for the marking of option B and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle. 1. Beneficence requires active promotion of patient welfare, while nonmaleficence demands the avoidance of harm. 2. Non\u2010beneficence is best understood as a failure to act rather than an active wrong. 3. Clarity in ethical definitions prevents mismanagement and medicolegal issues. Recent ethical literature emphasizes the importance of active beneficence in health care, noting that omissions in care can lead to legal and professional repercussions. Updated guidelines in clinical ethics continually stress a balanced approach that supports patient welfare, particularly in complex cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Definition of euthanasia:",
    "option_a": "Physician help patient with medication to end his life.",
    "option_b": "and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuropsychiatry",
    "explanation": "The concept centers on the idea of non\u2010beneficence, which is essentially the failure to promote the patient\u2019s best interests. In ethical terms, beneficence is the active duty to help and improve a patient\u2019s welfare. Non\u2010beneficence, although not classically listed as one of the key ethical principles, is used to describe situations where this positive duty is not fulfilled. It is important not to confuse this with nonmaleficence, which focuses on avoiding harm. While pathophysiology usually refers to disease mechanisms, in ethics the underlying mechanism is the lack of action to promote benefit. In this context, non\u2010beneficence occurs when a clinician, due to oversight or other factors, fails to take positive steps that would contribute to a patient\u2019s well\u2010being. Contemporary discussions stress that clinicians must actively engage in beneficent behaviors rather than simply avoiding harm. In clinical practice, a lapse of beneficence can be seen when appropriate therapies, support, or interventions are not offered to the patient, potentially leading to worsening outcomes. This concept is central to medical ethics and quality care, ensuring that all patients receive interventions aimed at improving their health. Although not a disease diagnosis, understanding non\u2010beneficence involves differentiating it from: (1) Beneficence (the duty to actively help), (2) Nonmaleficence (the duty to avoid harm), (3) Autonomy (respecting patient choices even if they conflict with beneficence), and (4) Justice (fairness in care delivery). In clinical settings, the approach is to ensure that beneficence is maximized. This involves keeping current with evidence based guidelines, individualized patient care planning, and an ethical commitment to improving patient outcomes. In scenarios involving special populations (eg, pregnant or lactating patients), beneficence dictates that clinicians consider the best available evidence to promote both maternal and fetal/infant health. Since no explicit options were provided except for the marking of option B and the analysis focused on clarifying definitions, option B (as marked) is taken as correct in this context. Common misinterpretations include confusing non\u2010beneficence with nonmaleficence or assuming it as an independent ethical principle. 1. Beneficence requires active promotion of patient welfare, while nonmaleficence demands the avoidance of harm. 2. Non\u2010beneficence is best understood as a failure to act rather than an active wrong. 3. Clarity in ethical definitions prevents mismanagement and medicolegal issues. Recent ethical literature emphasizes the importance of active beneficence in health care, noting that omissions in care can lead to legal and professional repercussions. Updated guidelines in clinical ethics continually stress a balanced approach that supports patient welfare, particularly in complex cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Definition of euthanasia",
    "option_a": "A Doctor prescribes or administer a drug to end the patient\u2019s life",
    "option_b": "The physician provides the means by which the patient can end his life",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Euthanasia is the practice of intentionally ending a person\u2019s life, at the explicit request of a competent patient, in order to relieve intractable suffering. It is an ethically and legally complex topic that distinguishes between active euthanasia (where the physician directly administers a lethal agent) and passive euthanasia (withdrawing or withholding life\u2010sustaining treatment). Although not a disease process, the ethical and legal debate around euthanasia centers on the intentional induction of death. In clinical settings\u2014especially in terminal or severely disabling illnesses\u2014the focus is on alleviating suffering. The mechanism isn\u2019t biological but involves careful evaluation of patient capacity, symptom burden, and the irreversible nature of the underlying condition. Clinicians may encounter euthanasia discussions in end\u2010of\u2010life care contexts, especially in patients with terminal illnesses or intractable pain. A clear understanding of the distinctions (e.g., active euthanasia vs. physician\u2010assisted suicide) is vital when counseling patients and families regarding options and legal ramifications. While euthanasia is not diagnosed, differentiating it from physician\u2010assisted suicide (PAS) is important. In PAS, the physician provides the means (such as prescribing a lethal dose) for the patient to self-administer, whereas in active euthanasia, the physician performs the final act of administration. Other end\u2010of\u2010life decisions include palliative sedation and withdrawal of care, each with distinct ethical and clinical guidelines. There is no medical treatment per se for euthanasia; instead, its practice is governed by legal frameworks and ethical guidelines. In regions where it is legal, strict protocols exist including confirmation of terminal illness, multiple clinical assessments, and explicit informed consent. For pregnant or lactating patients, additional ethical, legal, and societal considerations substantially complicate the issue, and most guidelines do not support euthanasia in these populations. Option A states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision. 1) Always distinguish between active euthanasia (physician administers the drug) and physician\u2010assisted suicide (patient self-administers after receiving a prescription). 2) Legal criteria for euthanasia are extremely strict and vary widely by jurisdiction. 3) Ethical debates continue to evolve, emphasizing patient autonomy and the relief of suffering. Recent research and guidelines emphasize multidisciplinary assessments and advanced care planning. Euthanasia remains a controversial issue, with evolving legal standards and ethical debates; current recommendations stress a careful balance between patient autonomy, beneficence, and non\u2010maleficence.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "To act in the best interest of the patient:",
    "option_a": "states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Euthanasia is the practice of intentionally ending a person\u2019s life, at the explicit request of a competent patient, in order to relieve intractable suffering. It is an ethically and legally complex topic that distinguishes between active euthanasia (where the physician directly administers a lethal agent) and passive euthanasia (withdrawing or withholding life\u2010sustaining treatment). Although not a disease process, the ethical and legal debate around euthanasia centers on the intentional induction of death. In clinical settings\u2014especially in terminal or severely disabling illnesses\u2014the focus is on alleviating suffering. The mechanism isn\u2019t biological but involves careful evaluation of patient capacity, symptom burden, and the irreversible nature of the underlying condition. Clinicians may encounter euthanasia discussions in end\u2010of\u2010life care contexts, especially in patients with terminal illnesses or intractable pain. A clear understanding of the distinctions (e.g., active euthanasia vs. physician\u2010assisted suicide) is vital when counseling patients and families regarding options and legal ramifications. While euthanasia is not diagnosed, differentiating it from physician\u2010assisted suicide (PAS) is important. In PAS, the physician provides the means (such as prescribing a lethal dose) for the patient to self-administer, whereas in active euthanasia, the physician performs the final act of administration. Other end\u2010of\u2010life decisions include palliative sedation and withdrawal of care, each with distinct ethical and clinical guidelines. There is no medical treatment per se for euthanasia; instead, its practice is governed by legal frameworks and ethical guidelines. In regions where it is legal, strict protocols exist including confirmation of terminal illness, multiple clinical assessments, and explicit informed consent. For pregnant or lactating patients, additional ethical, legal, and societal considerations substantially complicate the issue, and most guidelines do not support euthanasia in these populations. Option A states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision. 1) Always distinguish between active euthanasia (physician administers the drug) and physician\u2010assisted suicide (patient self-administers after receiving a prescription). 2) Legal criteria for euthanasia are extremely strict and vary widely by jurisdiction. 3) Ethical debates continue to evolve, emphasizing patient autonomy and the relief of suffering. Recent research and guidelines emphasize multidisciplinary assessments and advanced care planning. Euthanasia remains a controversial issue, with evolving legal standards and ethical debates; current recommendations stress a careful balance between patient autonomy, beneficence, and non\u2010maleficence.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Definition of informed consent:",
    "option_a": "states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Euthanasia is the practice of intentionally ending a person\u2019s life, at the explicit request of a competent patient, in order to relieve intractable suffering. It is an ethically and legally complex topic that distinguishes between active euthanasia (where the physician directly administers a lethal agent) and passive euthanasia (withdrawing or withholding life\u2010sustaining treatment). Although not a disease process, the ethical and legal debate around euthanasia centers on the intentional induction of death. In clinical settings\u2014especially in terminal or severely disabling illnesses\u2014the focus is on alleviating suffering. The mechanism isn\u2019t biological but involves careful evaluation of patient capacity, symptom burden, and the irreversible nature of the underlying condition. Clinicians may encounter euthanasia discussions in end\u2010of\u2010life care contexts, especially in patients with terminal illnesses or intractable pain. A clear understanding of the distinctions (e.g., active euthanasia vs. physician\u2010assisted suicide) is vital when counseling patients and families regarding options and legal ramifications. While euthanasia is not diagnosed, differentiating it from physician\u2010assisted suicide (PAS) is important. In PAS, the physician provides the means (such as prescribing a lethal dose) for the patient to self-administer, whereas in active euthanasia, the physician performs the final act of administration. Other end\u2010of\u2010life decisions include palliative sedation and withdrawal of care, each with distinct ethical and clinical guidelines. There is no medical treatment per se for euthanasia; instead, its practice is governed by legal frameworks and ethical guidelines. In regions where it is legal, strict protocols exist including confirmation of terminal illness, multiple clinical assessments, and explicit informed consent. For pregnant or lactating patients, additional ethical, legal, and societal considerations substantially complicate the issue, and most guidelines do not support euthanasia in these populations. Option A states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision. 1) Always distinguish between active euthanasia (physician administers the drug) and physician\u2010assisted suicide (patient self-administers after receiving a prescription). 2) Legal criteria for euthanasia are extremely strict and vary widely by jurisdiction. 3) Ethical debates continue to evolve, emphasizing patient autonomy and the relief of suffering. Recent research and guidelines emphasize multidisciplinary assessments and advanced care planning. Euthanasia remains a controversial issue, with evolving legal standards and ethical debates; current recommendations stress a careful balance between patient autonomy, beneficence, and non\u2010maleficence.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Definition of euthanasia",
    "option_a": "states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Euthanasia is the practice of intentionally ending a person\u2019s life, at the explicit request of a competent patient, in order to relieve intractable suffering. It is an ethically and legally complex topic that distinguishes between active euthanasia (where the physician directly administers a lethal agent) and passive euthanasia (withdrawing or withholding life\u2010sustaining treatment). Although not a disease process, the ethical and legal debate around euthanasia centers on the intentional induction of death. In clinical settings\u2014especially in terminal or severely disabling illnesses\u2014the focus is on alleviating suffering. The mechanism isn\u2019t biological but involves careful evaluation of patient capacity, symptom burden, and the irreversible nature of the underlying condition. Clinicians may encounter euthanasia discussions in end\u2010of\u2010life care contexts, especially in patients with terminal illnesses or intractable pain. A clear understanding of the distinctions (e.g., active euthanasia vs. physician\u2010assisted suicide) is vital when counseling patients and families regarding options and legal ramifications. While euthanasia is not diagnosed, differentiating it from physician\u2010assisted suicide (PAS) is important. In PAS, the physician provides the means (such as prescribing a lethal dose) for the patient to self-administer, whereas in active euthanasia, the physician performs the final act of administration. Other end\u2010of\u2010life decisions include palliative sedation and withdrawal of care, each with distinct ethical and clinical guidelines. There is no medical treatment per se for euthanasia; instead, its practice is governed by legal frameworks and ethical guidelines. In regions where it is legal, strict protocols exist including confirmation of terminal illness, multiple clinical assessments, and explicit informed consent. For pregnant or lactating patients, additional ethical, legal, and societal considerations substantially complicate the issue, and most guidelines do not support euthanasia in these populations. Option A states 'A Doctor prescribes or administer a drug to end the patient\u2019s life.' Although the phrase 'prescribes or administers' is ambiguous (since prescribing the drug is more aligned with PAS), the inclusion of 'administers' indicates active involvement by the doctor and aligns more closely with the concept of active euthanasia. Option B, by contrast, describes the scenario where the physician merely provides the means, which is the classical definition of PAS. Given the alternatives, Option A is acceptable as the intended answer for euthanasia despite its imprecision. 1) Always distinguish between active euthanasia (physician administers the drug) and physician\u2010assisted suicide (patient self-administers after receiving a prescription). 2) Legal criteria for euthanasia are extremely strict and vary widely by jurisdiction. 3) Ethical debates continue to evolve, emphasizing patient autonomy and the relief of suffering. Recent research and guidelines emphasize multidisciplinary assessments and advanced care planning. Euthanasia remains a controversial issue, with evolving legal standards and ethical debates; current recommendations stress a careful balance between patient autonomy, beneficence, and non\u2010maleficence.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "45-year-old male with poor sleeping and recent mood changes, early awakening as reported by his wife and they asked about what is true?",
    "option_a": "Diffuse low glucose uptake in PET scan",
    "option_b": "Increased temporalis single in EMG",
    "option_c": "Absence of beta activity in EEG",
    "option_d": "Increased cortisol levels in the night",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Major depressive disorder (MDD) is characterized by disturbances in mood and sleep, including symptoms like early morning awakening. A well\u2010documented biological correlate in depression is the disruption of the hypothalamic-pituitary-adrenal (HPA) axis, leading to abnormal cortisol secretion patterns. In depression, stress and impaired negative feedback mechanisms in the HPA axis result in increased cortisol secretion, especially during the night. This abnormal cortisol diurnal rhythm is believed to contribute to sleep disturbances and has been linked with the severity of depressive symptoms. Numerous studies have confirmed hypercortisolemia in patients with melancholic features of depression. The patient\u2019s early morning awakening and mood changes are typical of melancholic depression. Elevated nocturnal cortisol levels correlate with these clinical symptoms, supporting the diagnosis of MDD. The differential diagnosis should include other causes of insomnia (like primary sleep disorders, thyroid dysfunction, or Cushing's syndrome) and mood disorders. Laboratory assessments, including cortisol measurements and possibly a dexamethasone suppression test, can help differentiate depression from endocrine disorders. First-line treatment includes antidepressants (typically SSRIs) and psychotherapy. In pregnant and lactating women, SSRIs such as sertraline are preferred due to their safety profile, while non-pharmacological therapies and careful monitoring should be considered. Second-line treatments include SNRIs, atypical antidepressants, or augmentation strategies in refractory cases. Option A (Diffuse low glucose uptake in PET scan) is not characteristic of depression. Option B (Increased temporalis signal in EMG) is unrelated to depression. Option C (Absence of beta activity in EEG) does not align with depression\u2019s typical findings. Option D (Increased cortisol levels in the night) accurately reflects the hypercortisolemia often seen in patients with depression. 1. Early morning awakening is a hallmark of melancholic depression. 2. Elevated nocturnal cortisol levels are linked with HPA axis dysregulation in depression. 3. Biological markers such as cortisol may help in understanding disease severity. Recent research continues to validate the role of HPA axis dysregulation in depression, with studies suggesting that nocturnal hypercortisolemia may serve as a biomarker for melancholic depression. Updated clinical guidelines endorse the use of SSRIs as first-line therapy with specific considerations for pregnant and lactating patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Female with abnormal movements and greenish corneal ring (KF rings) What's the most common psychiatric presentation:",
    "option_a": "(Depression) is correct as it represents the most common psychiatric manifestation in Wilson disease. Option B (Mania) and Option C (Psychosis) are less common presentations. The emphasis on mood disturbances, particularly depression, is supported by clinical studies in Wilson disease.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Wilson disease is an autosomal recessive disorder of copper metabolism. Its hallmark features include hepatic dysfunction, neurological abnormalities, and psychiatric disturbances. The presence of Kayser-Fleischer (KF) rings (greenish corneal deposits) is pathognomonic for the disease. Mutations in the ATP7B gene impair copper excretion by the liver, causing copper accumulation in the liver, brain, and cornea. Copper deposition in the brain can lead to neuropsychiatric manifestations, with mood disturbances such as depression being the most frequently observed psychiatric symptom. Patients often present with abnormal movements, psychiatric symptoms, and the classic KF rings on slit-lamp examination. Depression in Wilson disease is typically more prevalent than other psychiatric conditions like mania or psychosis. Diagnostic workup includes measuring serum ceruloplasmin, 24-hour urinary copper excretion, hepatic copper quantification, and an ophthalmologic exam for KF rings. Differential diagnoses include other causes of movement disorders and psychiatric conditions without KF rings. First-line therapy is chelation with agents such as D-penicillamine or trientine. Zinc is used as maintenance therapy. When psychiatric symptoms occur, clinicians may need to treat with antidepressants (e.g., SSRIs) while closely monitoring for potential drug interactions. In pregnant or lactating patients, careful consideration and a multidisciplinary approach are required since chelation therapy might need adjustments based on potential teratogenic risks. Option A (Depression) is correct as it represents the most common psychiatric manifestation in Wilson disease. Option B (Mania) and Option C (Psychosis) are less common presentations. The emphasis on mood disturbances, particularly depression, is supported by clinical studies in Wilson disease. 1. KF rings are highly suggestive of Wilson disease. 2. Depression is the most common psychiatric presentation in Wilson disease. 3. Early diagnosis and treatment are critical to prevent irreversible neurological damage. Recent studies emphasize that neuropsychiatric symptoms, particularly depression, may appear early in Wilson disease. Updated management protocols now advocate for early chelation therapy along with psychiatric support, with specific guidelines for use during pregnancy and lactation.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Drug company is providing a new drug similar to an already existing one with the same usages and side effects but more expensive and they offered to give you 10% of the money, your action?",
    "option_a": "Give them your IBAN",
    "option_b": "tell them to make it 25%",
    "option_c": "refuse and ignore the meeting",
    "option_d": "Refuse and report them to Nezaha",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuropsychiatry",
    "explanation": "Medical ethics demand that physicians maintain unbiased clinical judgment. Accepting financial incentives or kickbacks from pharmaceutical companies undermines the integrity of clinical practice and can adversely influence patient care. While not biological in nature, the core issue is the ethical compromise that results from accepting bribes. Financial gains tied to prescribing behaviors can lead to conflicts of interest, ultimately harming patient trust and outcomes. Although this scenario does not directly impact patient physiology, unethical behavior in clinical practice can lead to biased treatment choices and endanger patient wellbeing by prioritizing profit over patient care. Ethically, the physician must assess the situation, recognize the potential conflict of interest, and choose an action that safeguards patient trust and professional integrity. Differential courses of action range from passive refusal to proactive reporting. The appropriate management is a tiered ethical response: first, refuse any financial incentive; second, report the unethical behavior to the proper authority\u2014in this case, Nezaha, the anti-corruption agency. These steps help ensure transparency and maintain public trust. Ethical standards remain unchanged regardless of personal circumstances, including pregnancy or lactation. Option A (Give them your IBAN) indicates acceptance of unethical funds. Option B (Tell them to make it 25%) shows further unethical intent. Option C (Refuse and ignore the meeting) does not adequately address the potential for recurring unethical practices. Option D (Refuse and report them to Nezaha) is the correct, ethically sound response as it both declines the bribe and holds the company accountable. 1. Always maintain separation between industry incentives and clinical decision-making. 2. Reporting unethical practices is critical to uphold medical integrity. 3. Transparency in all clinical interactions is a cornerstone of ethical practice. Recent updates in medical ethics guidelines from bodies such as the AMA and international health organizations clearly denounce accepting kickbacks. Studies on conflict of interest have shown that such practices can adversely impact clinical decisions, underscoring the need for strict adherence to ethical standards.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]